203 related articles for article (PubMed ID: 34237074)
1. Stopping azithromycin mass drug administration for trachoma: A systematic review.
Mahmud H; Landskroner E; Amza A; Aragie S; Godwin WW; de Hostos Barth A; O'Brien KS; Lietman TM; Oldenburg CE
PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009491. PubMed ID: 34237074
[TBL] [Abstract][Full Text] [Related]
2. Community-level Association between Clinical Trachoma and Ocular Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of Niger.
Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Porco TC; Keenan JD; Lietman TM; Oldenburg CE
Ophthalmic Epidemiol; 2019 Aug; 26(4):231-237. PubMed ID: 30957594
[No Abstract] [Full Text] [Related]
3. Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II).
Keenan JD; Tadesse Z; Gebresillasie S; Shiferaw A; Zerihun M; Emerson PM; Callahan K; Cotter SY; Stoller NE; Porco TC; Oldenburg CE; Lietman TM
PLoS Med; 2018 Aug; 15(8):e1002633. PubMed ID: 30106956
[TBL] [Abstract][Full Text] [Related]
4. Impact of a single round of mass drug administration with azithromycin on active trachoma and ocular Chlamydia trachomatis prevalence and circulating strains in The Gambia and Senegal.
Harding-Esch EM; Holland MJ; Schémann JF; Sillah A; Sarr B; Christerson L; Pickering H; Molina-Gonzalez S; Sarr I; Andreasen AA; Jeffries D; Grundy C; Mabey DCW; Herrmann B; Bailey RL
Parasit Vectors; 2019 Oct; 12(1):497. PubMed ID: 31640755
[TBL] [Abstract][Full Text] [Related]
5. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
Yohannan J; Munoz B; Mkocha H; Gaydos CA; Bailey R; Lietman TA; Quinn T; West SK
JAMA Ophthalmol; 2013 Apr; 131(4):431-6. PubMed ID: 23392481
[TBL] [Abstract][Full Text] [Related]
6. The effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged children.
Lee JS; Muñoz BE; Mkocha H; Gaydos CA; Quinn TC; West SK
PLoS Negl Trop Dis; 2014 Apr; 8(4):e2761. PubMed ID: 24722392
[TBL] [Abstract][Full Text] [Related]
7. The conjunctival microbiome before and after azithromycin mass drug administration for trachoma control in a cohort of Tanzanian children.
Pickering H; Ramadhani AM; Massae P; Mafuru E; Malisa A; Mbuya K; Makupa W; Mtuy T; Derrick T; Houghton J; Bailey RL; Mabey DCW; Burton MJ; Holland MJ
Front Public Health; 2022; 10():1015714. PubMed ID: 36324475
[TBL] [Abstract][Full Text] [Related]
8. Azithromycin Reduction to Reach Elimination of Trachoma (ARRET): study protocol for a cluster randomized trial of stopping mass azithromycin distribution for trachoma.
Amza A; Kadri B; Nassirou B; Arzika AM; Austin A; Nyatigo F; Lebas E; Arnold BF; Lietman TM; Oldenburg CE
BMC Ophthalmol; 2021 Jan; 21(1):15. PubMed ID: 33407263
[TBL] [Abstract][Full Text] [Related]
9. Trachoma prevalence remains below threshold in five districts after stopping mass drug administration: results of five surveillance surveys within a hyperendemic setting in Amhara, Ethiopia.
Nash SD; Stewart AEP; Astale T; Sata E; Zerihun M; Gessese D; Melak B; Ayenew G; Ayele Z; Bayissasse B; Chanyalew M; Tadesse Z; Callahan EK
Trans R Soc Trop Med Hyg; 2018 Dec; 112(12):538-545. PubMed ID: 30265355
[TBL] [Abstract][Full Text] [Related]
10. Mass drug administration of azithromycin for trachoma reduces the prevalence of genital Chlamydia trachomatis infection in the Solomon Islands.
Marks M; Bottomley C; Tome H; Pitakaka R; Butcher R; Sokana O; Kako H; Solomon AW; Mabey DC
Sex Transm Infect; 2016 Jun; 92(4):261-5. PubMed ID: 26888658
[TBL] [Abstract][Full Text] [Related]
11. Antibiotics for trachoma.
Evans JR; Solomon AW; Kumar R; Perez Á; Singh BP; Srivastava RM; Harding-Esch E
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD001860. PubMed ID: 31554017
[TBL] [Abstract][Full Text] [Related]
12. The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa.
Last AR; Burr SE; Harding-Esch E; Cassama E; Nabicassa M; Roberts CH; Mabey DCW; Holland MJ; Bailey RL
Parasit Vectors; 2017 Dec; 10(1):624. PubMed ID: 29282126
[TBL] [Abstract][Full Text] [Related]
13. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia.
Harding-Esch EM; Sillah A; Edwards T; Burr SE; Hart JD; Joof H; Laye M; Makalo P; Manjang A; Molina S; Sarr-Sissoho I; Quinn TC; Lietman T; Holland MJ; Mabey D; West SK; Bailey R;
PLoS Negl Trop Dis; 2013; 7(6):e2115. PubMed ID: 23785525
[TBL] [Abstract][Full Text] [Related]
14. Ocular immune responses, Chlamydia trachomatis infection and clinical signs of trachoma before and after azithromycin mass drug administration in a treatment naïve trachoma-endemic Tanzanian community.
Ramadhani AM; Derrick T; Macleod D; Massae P; Malisa A; Mbuya K; Mtuy T; Makupa W; Roberts CH; Bailey RL; Mabey DCW; Holland MJ; Burton MJ
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007559. PubMed ID: 31306419
[TBL] [Abstract][Full Text] [Related]
15. Pgp3 seroprevalence and associations with active trachoma and ocular Chlamydia trachomatis infection in Malawi: cross-sectional surveys in six evaluation units.
Burr SE; Hart J; Samikwa L; Chaima D; Cooley G; Martin D; Masika M; Solomon AW; Bailey RL; Kalua K
PLoS Negl Trop Dis; 2019 Oct; 13(10):e0007749. PubMed ID: 31658258
[TBL] [Abstract][Full Text] [Related]
16. Community-level chlamydial serology for assessing trachoma elimination in trachoma-endemic Niger.
Kim JS; Oldenburg CE; Cooley G; Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Keenan JD; Gaynor BD; Porco TC; Lietman TM; Martin DL
PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007127. PubMed ID: 30689671
[TBL] [Abstract][Full Text] [Related]
17. Population-based coverage survey results following the mass drug administration of azithromycin for the treatment of trachoma in Amhara, Ethiopia.
Astale T; Sata E; Zerihun M; Nute AW; Stewart AEP; Gessese D; Ayenew G; Melak B; Chanyalew M; Tadesse Z; Callahan EK; Nash SD
PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006270. PubMed ID: 29451881
[TBL] [Abstract][Full Text] [Related]
18. A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution.
Morberg DP; Alemayehu W; Melese M; Lakew T; Sisay A; Zhou Z; Cevallos V; Oldenburg CE; Porco TC; Lietman TM; Keenan JD
Ophthalmic Epidemiol; 2019 Feb; 26(1):19-26. PubMed ID: 30153085
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review.
O'Brien KS; Emerson P; Hooper PJ; Reingold AL; Dennis EG; Keenan JD; Lietman TM; Oldenburg CE
Lancet Infect Dis; 2019 Jan; 19(1):e14-e25. PubMed ID: 30292480
[TBL] [Abstract][Full Text] [Related]
20. Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study.
Harding-Esch E; Jofre-Bonet M; Dhanjal JK; Burr S; Edwards T; Holland M; Sillah A; West S; Lietman T; Keenan J; Mabey D; Bailey R
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003670. PubMed ID: 25901349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
